Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31248639 | 1.00 | KMT2A (0.34) | KMT2AMEN1L3MBTL1BRPF1EGFR | |
| SCHEMBL31248637 | 0.87 | BRPF1 (0.43) | KMT2AMEN1L3MBTL1BRPF1EGFR | |
| SCHEMBL26547632 | 0.84 | CYP19A1 (0.43) | KMT2AMEN1L3MBTL1BRPF1EGFR | |
| SCHEMBL26547732 | 0.83 | ACACB (0.38) | KMT2AMEN1L3MBTL1BRPF1EGFR | |
| SCHEMBL31248652 | 0.81 | MEN1 (0.34) | KMT2AMEN1L3MBTL1BRPF1EGFR | |
| SCHEMBL31248757 | 0.81 | SMN1; SMN2 (0.37) | KMT2AMEN1L3MBTL1BRPF1EGFR | |
| SCHEMBL31248756 | 0.77 | MEN1 (0.34) | KMT2AMEN1L3MBTL1BRPF1EGFR | |
| SCHEMBL26547697 | 0.76 | ALDH1A1 (0.36) | KMT2AMEN1L3MBTL1EGFRLMNA | |
| SCHEMBL31426258 | 0.76 | BRPF1 (0.40) | KMT2AMEN1L3MBTL1BRPF1LMNA | |
| SCHEMBL26547742 | 0.76 | BRPF1 (0.40) | KMT2AMEN1L3MBTL1BRPF1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | KMT2A 227/4885MEN1 2797/4885L3MBTL1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.